Given the unpredictability of severe disease development, early administration of type 1 IFN treatment is one of many probable treatments that may be beneficial in patients with severe COVID-19 since there is an early loss-of-function phenotype in IFN signaling (Lee and Shin, 2020; Pairo-Castineira et al., 2021). The gene discussed is IFNA1; the disease is COVID-19.